Canadian Cancer Trials Group Bulletins

Trial Management Group

Trials Closed to Accrual

Canadian Cancer Trials Group IND.181

IND.181 -- Canadian Cancer Trials Group Phase I Study of AT9283 Given as a 24-hour Intravenous Infusion on Days 1 and 8 Every Three weeks in Patients with Advanced Incurable Malignancy -- was permanently closed 24 November 2009 having achieved its objectives.

Between January 2007 and November 2009, a total of 35 patients were entered on this study at 9 dose levels, ranging from 1.5 to 47 mg/m2/day.

The phase II recommended dose was defined as 40 mg/m2/day.

Canadian Cancer Trials Group CRC.2 / NCCTG 0147

Canadian Cancer Trials Group CRC.2 / NCCTG 0147 -- A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer -- was closed to further accrual effective November 25th at 5pm EST.

In a meeting conducted by the Data Monitoring Committee (DMC) of the NCCTG to review a pre-planned interim analysis, it was determined that the addition of cetuximab to FOLFOX was of no benefit in this clinical trial.

For more information about closure of this trial, please go to the trial website at